Core Insights - LivaNova PLC presented its strategic roadmap and long-range financial plan during its 2025 Investor Day, outlining targets for revenue and earnings per share (EPS) growth by 2030 [1][2] Financial Targets - The company aims for a high-single-digit-plus revenue compound annual growth rate (CAGR) [4] - Adjusted annual operating margin is projected to exceed 20% over the next three years, targeting high twenties by 2030 [4] - Earnings-per-share CAGR is expected to be in the low double digits to mid-teens [4] - Adjusted free cash flow conversion is anticipated to be above 80% [4] Business Segments - Cardiopulmonary business operates in a $2 billion global market, with expected mid-to-high single-digit revenue CAGR and adjusted operating margin expansion of over 300 basis points by 2030 [4] - In the Epilepsy segment, the company expects mid-single-digit revenue CAGR and adjusted operating income margin expansion of approximately 200 basis points by 2030, supported by real-world evidence and new product launches [4] - The Obstructive Sleep Apnea (OSA) market is targeted with differentiated technology, projected to generate $200 million to $400 million in revenue by 2030 and adjusted operating income margin of greater than 25% [5] Strategic Initiatives - LivaNova is focused on maximizing core businesses, scaling OSA, and preserving upside in Difficult-to-Treat Depression (DTD) [3][4] - The company plans to commercialize its OSA product independently in 2027, retaining full control over pricing and customer relationships [5] - DTD remains a strategic extension of its Neuromodulation platform, with potential value creation pending coverage reconsideration by the U.S. Centers for Medicare & Medicaid Services [5]